Pheochromocytoma and Paraganglioma

How to Cite This Chapter: Bahrami J, Prebtani APH, Januszewicz W, Januszewicz A, Prejbisz A. Pheochromocytoma and Paraganglioma. McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. https://empendium.com/mcmtextbook/chapter/B31.II.11.11.?utm_source=nieznany&utm_medium=referral&utm_campaign=social-chapter-link Accessed December 02, 2021.
Last Updated: December 3, 2020
Last Reviewed: December 3, 2020
Chapter Information

Definition, Etiology, PathogenesisTop

Pheochromocytoma (PCC) and paraganglioma (PGL) are catecholamine-secreting tumors that arise from chromaffin cells of the adrenal medulla and extra-adrenal sympathetic ganglia, respectively. The majority of these rare tumors occur sporadically. Approximately 40% occur as part of a familial syndrome, 10% are bilateral, 10% are extra-adrenal, 10% are found in children, 10% are recurrent, and <10% are malignant.

Hereditary PCC/PGL syndromes include multiple endocrine neoplasia types 2 and 3 (MEN 2, MEN 3), von Hippel-Lindau disease (VHL) (cerebroretinal angiomatosis), neurofibromatosis type 1 (NF1), Carney triad (gastrointestinal stromal tumor, pulmonary chondromas, and functional extra-adrenal paragangliomas), and mutations in the succinate dehydrogenase (SDH) genes.

PCC and PGL are rare causes of hypertension and account for 0.1% to 0.6% of all cases of hypertension.

Clinical Features and Natural HistoryTop

The classic triad, in addition to hypertension, includes paroxysmal headaches, palpitations, and sweating. Other symptoms and signs include paroxysmal hypertension, pallor, postural hypotension, anxiety, weight loss, and panic attacks (see Table 6.1-1). Of note, similar symptoms may occur during nonspecific “spells” (a sudden onset of a symptom or symptoms that are stereotypic and self-limited and may be recurrent) related to transient adrenergic activation. Additional clues to consider screening for PCC/PGL include unexplained variability of blood pressure; paradoxical blood pressure response to anesthesia, surgery, or certain drugs; extremes of age; hypertension resistant to >3 drugs; syndrome associated with PCC or PGL; or a family history suggestive of a hereditary PCC or PGL syndrome.

Complications include cardiomyopathy, congestive heart failure, end-organ damage due to hypertension, arrhythmias, and death if the condition is uncontrolled or untreated.

DiagnosisTop

Screening

Screening should be considered in patients with suggestive clinical features (see above). It should also be discussed if there is an incidentally discovered adrenal or retroperitoneal mass with ≥10 Hounsfield unit attenuation on unenhanced computed tomography (CT) and the patient is known to be a carrier of disease-causing genetic mutations of syndromes (eg, mutations in RET [MEN 2, MEN 3]), VHL, SDHx, or NF1 genes).

Diagnostic Tests

1. Laboratory tests: Elevated 24-hour urine fractionated metanephrine levels and plasma metanephrine levels have a high sensitivity. Mild elevations can be nonspecific and nondiagnostic, but elevations >2 to 3 × the upper limit of normal (ULN) may be diagnostic. Many medications and other substances can interfere with biochemical testing and should be discontinued 1 to 2 weeks prior to testing, if possible. These include acetaminophen (INN paracetamol), tricyclic antidepressants (TCAs), levodopa, amphetamines, most psychoactive agents, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), cocaine, beta-blockers, alpha-blockers, and sympathomimetics, among others (see Table 6.1-2). Always ask the patient about herbal therapies, supplements, and nonprescribed agents.

2. Anatomic imaging: After making the diagnosis based on clinical and biochemical criteria, it is critical to localize the tumor(s) with imaging studies. Imaging should never be pursued prior to clinical and biochemical confirmation. Localization is initially by contrast-enhanced CT (high sensitivity) or T2-weighted magnetic resonance imaging (MRI) (high sensitivity and moderate specificity) of the abdomen. If this fails to locate a tumor, proceed to whole-body CT or MRI to localize extra-abdominal PGL.

3. Functional/molecular imaging (done in specialized settings): Functional/molecular imaging should be done if results of anatomic imaging are equivocal or in case of searching for extra-adrenal PGL, multiple/bilateral suspected tumors, or metastatic disease. Imaging modalities include scintigraphy with 68Ga-DOTATATE positron emission tomography with computed tomography (PET-CT), 123I-metaiodobenzylguanidine (MIBG) scintigraphy, or 18-fluorodeoxyglucose (FDG) PET-CT.

1) 68Ga-DOTATATE PET-CT can effectively localize the tumor and potential metastases with high sensitivity unless the tumor is poorly differentiated.

2) 123I-MIBG can also be used to localize the tumor and potential metastases. This test is less sensitive than 68Ga-DOTATATE PET-CT. Medications such as labetalol, TCAs, and phenothiazines should be withheld for 4 to 6 weeks prior to imaging to reduce the risk of false-negative results.

3) 18FDG PET-CT is occasionally helpful if the above-listed functional/molecular imaging studies are negative and there is suspicion of a poorly differentiated tumor.

Results of molecular/functional imaging alone cannot be used as a surgical indication and must always be correlated with CT or MRI findings as well as clinical and biochemical data.

4. Genetic testing (done in specialized settings): Genetic testing can be considered in those with confirmed PCC or PGL who are aged <50 years, those who have clinical features of a genetic syndrome associated with PCC or PGL, those who have a family history of PCC/PGL, and those with multiple tumors, malignant tumors, or bilateral tumors.

Differential Diagnosis

Other causes of (resistant or refractory) hypertension and “spells” should always be excluded. Other differential diagnoses include thyrotoxicosis, carcinoid, panic attacks, cluster/migraine headaches, certain drugs and illicit substance use or withdrawal, autonomic dysfunction, and pseudopheochromocytoma (paroxysmal hypertension with a negative biochemical evaluation for pheochromocytoma).

TreatmentTop

Diagnostic algorithm for suspected PCC or PGL: Figure 6.1-1.

Surgical resection of the tumor is the mainstay of therapy. Surgery should be undertaken after medical optimization. The goals of preoperative medical therapy include optimal blood pressure and heart rate control to avoid perioperative morbidity and mortality associated with hypertensive crises, malignant arrhythmia, multiorgan failure, and volume expansion, as these patients are often volume contracted.

1. Medical optimization: Optimal blood pressure control with combined alpha- and beta-blockade is essential prior to planned surgery along with adequate hydration with generous fluid and sodium intake. Target blood pressure should be in the low-normal range for age while avoiding significant orthostatic hypotension or its symptoms. It is important to use alpha-blockade first, starting at least 10 to 14 days before surgery, and then follow with beta-blockade 3 to 4 days later (for controlling the risk of tachycardia and arrhythmia) to mitigate unopposed alpha-receptor stimulation, which could lead to catastrophic hypertension and cardiopulmonary decompensation. Other agents that could be added include dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs), but it is best to avoid diuretics if possible.

1) Alpha-adrenergic blockade: A nonselective alpha-blocker, for instance, phenoxybenzamine 10 mg bid as a starting dose and titrated up to 60 mg bid may be used. Alternatively, a selective alpha-1 adrenergic blocker such as doxazosin at a starting dose of 1 to 2 mg daily and titrated up to 16 mg bid may be used.

2) Beta-adrenergic blockade: Beta-blocker therapy is used to control tachycardia. Beta-blockers should be initiated a few days after adequate blood pressure control has been achieved with alpha-blockade to attain a target heart rate of 60 to 80 beats per minute.

2. Surgery:

1) PCC: Laparoscopic localized adrenalectomy by an experienced adrenal surgeon may be done for the majority of patients, especially if a small, unilateral, intra-adrenal tumor with nonmalignant features is found on imaging. Other patients may require open laparotomy.

2) PGL: These will require resection by a surgeon experienced in the particular site(s) where the tumor is located.

PrognosisTop

In PCC, adrenalectomy provides cure for the majority of patients if the tumor is not malignant. However, PCC may recur in ≤10% of patients and metastatic disease may also occur after surgical removal. In PGL, the prognosis depends on the size, site, completeness of resection, and malignant potential of the tumor.

Malignant PCCs/PGLs have a poorer prognosis and may require other therapies in a specialized multidisciplinary setting if they are progressive, persistent, or symptomatic. Treatments may include peptide receptor radionuclide therapy (PRRT), somatostatin analogues (SSAs), tyrosine kinase inhibitors (TKIs), radiotherapy, and chemotherapy. In addition, these patients may also have underlying essential hypertension requiring usual antihypertensive therapy (see Essential Hypertension). Therefore, long-term follow-up is necessary.

TABLES AND FIGURESTop

Table 6.1-1. Signs and symptoms of catecholamine-producing tumors

Clinical finding

Incidence (if known)

Hypertension

90%

Headache

80%

Perspiration

71%

Palpitations

64%

Pallor

42%

Postural hypotension

10%-50%

Paroxysms/“spells”

50%

Table 6.1-2. Medications/substances that may interfere with biochemical testing

 

Normetanephrines

Metanephrines

Plasma

Urine

Plasma

Urine

Acetaminophen

­­↑↑

­­↑↑

No change

No change

Labetalol

No change

­­↑↑

No change

­­↑↑

Sotalol

No change

­­↑↑

No change

­­↑↑

Alpha-methyldopa

­­↑↑

­­↑↑

No change

No change

Tricyclic antidepressants

­­↑↑

­­↑↑

No change

No change

Phenoxybenzamine

­­↑↑

↑↑­­

No change

No change

Monoamine oxidase inhibitors

­­↑↑

↑↑­­

­­↑↑

↑↑­­

Sympathomimetics

­↑

­↑

­↑

­↑

Levodopa

­↑

­­↑↑

­↑

­↑

Buspirone

No change

No change

­­↑↑

↑↑­­

Cocaine

­­↑↑

↑↑­­

­↑

­↑

Figure 6.1-1. Diagnostic algorithm for suspected pheochromocytoma/paraganglioma.

We would love to hear from you

Comments, mistakes, suggestions?

Partner

Industry Partners

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.